This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.
Updated results from a phase Ib dose-expansion study in UBC suggest that the anti–PD-L1 antibody atezolizumab yields greater efficacy in patients with higher expression of PD-L1 on immune cells.
Updated data from the urothelial cohort that demonstrate favorable and durable activity of pembrolizumab.
Randomized phase II trial results of a Hsp27 inhibitor suggest potential benefit among patients with poor prognostic features at baseline.
Results of this phase II study indicate promising response rates and survival in both tubulin inhibitor–naive and tubulin inhibitor–exposed patients.
Results of the first randomized, individualized therapy study in metastatic bladder cancer.
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.
Results of the largest controlled trial in metastatic nonclear-cell RCC show different efficacy among the VEGF-TKI and mTOR inhibitor in specific subgroups.
Results of a dose amendment to the phase III ASSURE trial; impact on safety and clinical outcome discussed.
Mutations in MTOR, TSC1, and TSC2, but not PTEN or PIK3CA, were associated with complete responses to mTOR inhibitors in patients with metastatic RCC.
Interesting results of a large randomized, multiarm, multistage trial that indicate a potential change in standard of care.
Biopsy study identified an important new histologic subtype, which when combined with SCNC, represents the largest group of AR therapy–resistant patients.
A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.
David F. McDermott, MD, and Daniel P. Petrylak, MD, provide their analysis of key genitourinary cancer presentations from the 2015 clinical oncology meeting in Chicago.
In this downloadable slideset, David F. McDermott, MD, and Daniel P. Petrylak, MD, review key studies presented at the 2015 American Society of Clinical Oncology Annual Meeting relevant to the management of patients with prostate, kidney, or bladder cancers.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.